DRAFT landscape of COVID-19 candidate vaccines – 11 April 2020 3 candidate vaccines in clinical evaluation Platform Type of candidate vaccine Developer CanSino Biological Inc./Beijing Institute of Biotechnology Coronavirus target NonReplicating Viral Vector Adenovirus Type 5 Vector DNA DNA plasmid Inovio vaccine Pharmaceuticals Electroporation device COVID-19 Phase 1 NCT04336410 RNA LNPencapsulated mRNA COVID-19 Phase 1 Moderna/NIAID COVID-19 Current stage of Same platform for clinical non-Coronavirus evaluation/regulatory candidates status- Coronavirus candidate Phase 2 Ebola ChiCTR2000031781 Phase 1 ChiCTR2000030906 Lassa, Nipah HIV Filovirus HPV Cancer indications Zika Hepatitis B multiple candidates NCT04283461 67 candidate vaccines in preclinical evaluation Platform Type of candidate vaccine Developer Coronavirus target DNA DNA with Karolinska Institute / electroporation Cobra Biologics (OPENCORONA Project) COVID-19 Current stage of clinical evaluation/regulatory status- Coronavirus candidate Pre-Clinical DNA DNA plasmid vaccine Osaka University/ AnGes/ Takara Bio COVID-19 Pre-Clinical DNA DNA Takis/Applied DNA Sciences/Evvivax COVID-19 Pre-Clinical DNA Plasmid DNA, Needle-Free Delivery Immunomic Therapeutics, COVID-19 Inc./EpiVax, Inc./PharmaJet, Inc. Pre-Clinical Same platform for non-Coronavirus candidates SARS DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. DNA DNA plasmid vaccine Zydus Cadila COVID-19 Pre-Clinical Inactivated Inactivated + alum Sinovac COVID-19 Pre-Clinical Inactivated Inactivated Beijing Institute of COVID-19 Biological Products/Wuhan Institute of Biological Products Pre-Clinical Inactivated TBD Osaka University/ BIKEN/ NIBIOHN COVID-19 Pre-Clinical Live Attenuated Virus Deoptimized live attenuated vaccines Codagenix/Serum Institute of India COVID-19 Pre-Clinical HAV, InfA, ZIKV, FMD, SIV, RSV, DENV NonReplicating Viral Vector ChAdOx1 University of Oxford COVID-19 Phase 1/2 (not yet recruiting) NCT04324606 MERS, influenza, TB, Chikungunya, Zika, MenB, plague NonReplicating Viral Vector MVA encoded VLP GeoVax/BravoVax COVID-19 Pre-Clinical LASV, EBOV, MARV, HIV NonReplicating Viral Vector Ad26 (alone or with MVA boost) Janssen Pharmaceutical Companies COVID-19 Pre-Clinical Ebola, HIV, RSV Nonreplicating viral vector MVA-S encoded DZIF – German Center for Infection Research COVID-19 Pre-clinical Many NonReplicating Viral Vector adenovirusAltimmune based NasoVAX expressing SARS2-CoV spike protein COVID-19 Pre-Clinical influenza NonReplicating Viral Vector Ad5 S (GREVAX™ platform) COVID-19 Pre-Clinical MERS Greffex SARS DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. NonReplicating Viral Vector Oral Vaccine platform Vaxart COVID-19 Pre-Clinical InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE NonReplicating Viral Vector MVA expressing structural proteins Centro Nacional Biotecnología (CNB-CSIC), Spain COVID-19 Pre-Clinical HIV, HCV, chikungunya, Ebola, zika, malaria, leishmania Protein Subunit Capsid-like Particle AdaptVac (PREVENT-nCoV COVID-19 consortium) Pre-Clinical Protein Subunit Drosophila S2 insect cell expression system VLPs ExpreS2ion COVID-19 Pre-Clinical Protein Subunit Peptide antigens formulated in lipid nanoparticle formulation S protein IMV Inc COVID-19 Pre-Clinical WRAIR/USAMRIID COVID-19 Pre-Clinical Protein Subunit S protein +Adjuvant National Institute of Infectious Disease, Japan COVID-19 Pre-Clinical Protein Subunit VLPrecombinant protein + Adjuvant Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan COVID-19 Pre-Clinical Protein Subunit Native like Trimeric subunit Spike Protein vaccine Clover Biopharmaceuticals Inc./GSK/Dynavax COVID-19 Pre-Clinical HIV, REV Influenza Protein Subunit microneedle arrays S1 subunit Univ. of Pittsburgh COVID-19 Pre-Clinical MERS Protein Subunit Peptide Vaxil Bio COVID-19 Pre-Clinical Protein Subunit Influenza DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Protein Subunit Adjuvanted Biological E Ltd protein subunit (RBD) COVID-19 Pre-Clinical Protein Subunit Peptide Flow Pharma Inc COVID-19 Pre-Clinical Protein Subunit S protein AJ Vaccines COVID-19 Pre-Clinical Protein Subunit Ii-Key peptide Generex/EpiVax COVID-19 Pre-Clinical Influenza, HIV, SARS-CoV Protein Subunit S protein EpiVax/Univ. of Georgia COVID-19 Pre-Clinical H7N9 Protein Subunit S protein (baculovirus production) Sanofi Pasteur COVID-19 Pre-Clinical Influenza, SARS-CoV Protein Subunit VLPrecombinant protein nanoparticle vaccine + Matrix M gp-96 backbone Novavax COVID-19 Pre-Clinical RSV; CCHF, HPV, VZV, EBOV Heat Biologics/Univ. Of Miami COVID-19 Pre-Clinical NSCLC, HIV, malaria, Zika Protein Subunit Molecular clamp stabilized Spike protein University of COVID-19 Queensland/GSK/Dynavax Pre-Clinical Nipah, influenza, Ebola, Lassa Protein Subunit S1 or RBD protein Baylor College of Medicine COVID-19 Pre-Clinical SARS Protein Subunit Subunit protein, plant produced iBio/CC-Pharming COVID-19 Pre-Clinical Protein Subunit Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Protein Subunit Recombinant protein, nanoparticles (based on Sprotein and other epitopes) COVID-19 XWG-03 truncated S (spike) proteins Saint-Petersburg scientific COVID-19 research institute of vaccines and serums Pre-Clinical Innovax/Xiamen Univ./GSK COVID-19 Pre-Clinical Protein Subunit Adjuvanted microsphere peptide VIDO-InterVac, University of Saskatchewan COVID-19 Pre-Clinical Protein Subunit Synthetic Long Peptide Vaccine candidate for S and M proteins OncoGen COVID-19 Pre-Clinical Replicating Viral Vector Measles Vector Zydus Cadila COVID-19 Pre-Clinical Replicating Viral Vector Measles Vector Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research COVID-19 Pre-Clinical West nile, chik, Ebola, Lassa, Zika Live attenuated virus Measles Virus (S, N targets) DZIF – German Center for Infection Research COVID-19 Pre-clinical Zika, H7N9, CHIKV Replicating Viral Vector Horsepox vector expressing S protein Tonix Pharma/Southern Research COVID-19 Pre-Clinical Smallpox, monkeypox Replicating Viral Vector Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) Influenza vector expressing RBD BiOCAD and IEM COVID-19 Pre-Clinical University of Hong Kong COVID-19 Pre-Clinical VSV vector expressing S protein IAVI/Batavia COVID-19 Pre-Clinical Protein Subunit Replicating Viral Vector Replicating Viral Vector HPV Ebola, Marburg, Lassa DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. RNA LNPencapsulated mRNA cocktail encoding VLP Fudan University/ Shanghai JiaoTong University/RNACure Biopharma COVID-19 Pre-Clinical RNA LNPencapsulated mRNA encoding RBD Fudan University/ Shanghai JiaoTong University/RNACure Biopharma COVID-19 Pre-Clinical RNA Replicating Centro Nacional Defective SARS- Biotecnología (CNB-CSIC), CoV-2 derived Spain RNAs COVID-19 Pre-Clinical RNA LNPencapsulated mRNA University of Tokyo/ Daiichi-Sankyo COVID-19 Pre-Clinical RNA Liposomeencapsulated mRNA BIOCAD COVID-19 Pre-Clinical RNA mRNA China CDC/Tongji University/Stermina COVID-19 Pre-Clinical RNA mRNA Arcturus/Duke-NUS COVID-19 Pre-Clinical RNA mRNA BioNTech/Fosun Pharma/Pfizer COVID-19 Pre-Clinical RNA saRNA Imperial College London COVID-19 Pre-Clinical EBOV; LASV, MARV, Inf (H7N9), RABV RNA mRNA Curevac COVID-19 Pre-Clinical RABV, LASV, YFV; MERS, InfA, ZIKV, DengV, NIPV VLP Virus-like particle, based on RBD displayed on virus-like particles Plant-derived VLP Saiba GmbH COVID-19 Pre-Clinical Medicago Inc. COVID-19 Pre-Clinical Imophoron Ltd and Bristol COVID-19 University’s Max Planck Centre ReiThera COVID-19 Pre-Clinical Unknown ADDomerTM multiepitope display Unknown Unknown Unknown BioNet Asia COVID-19 Pre-Clinical Unknown Unknown ImmunoPrecise COVID-19 Pre-Clinical Unknown Unknown MIGAL Galilee Research Institute COVID-19 Pre-Clinical VLP VLP MERS multiple candidates Flu, Rotavirus, Norovirus, West Nile virus, Cancer Pre-Clinical DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Unknown Unknown Doherty Institute COVID-19 Pre-Clinical Unknown Unknown Tulane University COVID-19 Pre-Clinical DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.